Stockscreener 앱 받기
2.20
7.95%
-0.19
시간 외 거래:
2.15
-0.05
-2.27%
전일 마감가:
$2.39
열려 있는:
$2.35
하루 거래량:
172.70K
Relative Volume:
1.01
시가총액:
$15.54M
수익:
$2.90M
순이익/손실:
$87.91M
주가수익비율:
0.1409
EPS:
15.6103
순현금흐름:
$-26.93M
1주 성능:
-14.40%
1개월 성능:
-2.22%
6개월 성능:
+54.93%
1년 성능:
-56.00%
1일 변동 폭
$2.13
$2.36
1주일 범위
$2.13
$3.10
52주 변동 폭
$0.97
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
명칭
Traws Pharma Inc
전화
267-759-3680
주소
12 PENNS TRAIL, NEWTOWN
TRAW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.20 | 17.03M | 2.90M | 87.91M | -26.93M | 15.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-18 | 개시 | Guggenheim | Buy |
| 2018-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-09 | 개시 | H.C. Wainwright | Buy |
| 2017-04-27 | 개시 | Laidlaw | Buy |
| 2015-07-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 개시 | H.C. Wainwright | Buy |
모두보기
Traws Pharma Inc 주식(TRAW)의 최신 뉴스
Can Traws Pharma Inc. (0T20) stock sustain institutional flowsQuarterly Portfolio Summary & AI Powered Market Entry Ideas - newser.com
Traws Pharma Adjusts Outlook Amid Strong Sales Growth and Market Challenges - Markets Mojo
What the charts say about Traws Pharma Inc. today2025 Major Catalysts & Accurate Technical Buy Alerts - newser.com
Why Traws Pharma Inc. is moving todayMarket Activity Report & High Accuracy Investment Signals - newser.com
Why ETFs are accumulating Traws Pharma Inc. (0T20) stockJuly 2025 Earnings & Safe Capital Growth Tips - newser.com
Advanced analytics toolkit walkthrough for Traws Pharma Inc.July 2025 Action & Risk Controlled Swing Trade Alerts - newser.com
Live market analysis of Traws Pharma Inc.July 2025 EndofMonth & Real-Time Stock Movement Alerts - newser.com
Visualizing Traws Pharma Inc. stock with heatmapsJobs Report & High Accuracy Trade Alerts - newser.com
Using RSI to spot recovery in Traws Pharma Inc.Weekly Risk Summary & Step-by-Step Trade Execution Guides - newser.com
Will Traws Pharma Inc. (0T20) stock extend growth story2025 Support & Resistance & Low Risk High Reward Trade Ideas - newser.com
Is Traws Pharma Inc. (0T20) stock supported by free cash flowPrice Action & Daily Stock Momentum Reports - newser.com
Technical signs of recovery in Traws Pharma Inc.2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
Measuring Traws Pharma Inc.’s beta against major indicesWatch List & Fast Gaining Stock Strategy Reports - newser.com
How Traws Pharma Inc. stock reacts to inflationary pressures2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com
Is Traws Pharma Inc. (0T20) stock testing key supportJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
What technical models suggest about Traws Pharma Inc.’s comebackEarnings Growth Report & Risk Controlled Daily Plans - newser.com
Price action breakdown for Traws Pharma Inc.July 2025 Weekly Recap & Fast Entry and Exit Trade Plans - newser.com
Is Traws Pharma Inc. forming a reversal patternMarket Activity Report & High Accuracy Investment Signals - newser.com
Traws Pharma (NASDAQ:TRAW) Upgraded at Wall Street Zen - Defense World
Tick level data insight on Traws Pharma Inc. volatilityPortfolio Gains Summary & Breakout Confirmation Alerts - newser.com
Is a relief rally coming for Traws Pharma Inc. holdersWeekly Trend Recap & Comprehensive Market Scan Insights - newser.com
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials - MarketScreener
2025-10-30 | ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials | NDAQ:TRAW | Press Release - Stockhouse
Traws Pharma Inc (TRAW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):